Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PAHC | 8-K | bullish | 6/10 | Phibro Animal Health reported Q3 FY2026 results with net sales of $383.5M (+10% YoY) and adjusted diluted EPS of $0.76, | May 6, 2026 |
| DMAC | 8-K | bearish | 6/10 | DiaMedica reported Q1 2026 EPS of -$0.19, missing consensus of -$0.17 by 11.8%. Net loss widened to $10.0M from $7.7M a | May 6, 2026 |
| ALVO | PRESS-RELEASE | bearish | 7/10 | Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due | May 6, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the dec | May 6, 2026 |
| SXT | CLUSTER | neutral | 2/10 | Two insiders at Sensient Technologies sold a combined $73K in open-market transactions within a week, a trivial 0.0015% | May 6, 2026 |
| ARGX | 6-K | neutral | 3/10 | argenx announced results of its Annual General Meeting and the appointment of Karen Massey as CEO, succeeding founder Ti | May 6, 2026 |
| ALTO | 8-K | mixed | 6/10 | Alto Ingredients reported Q1 2026 earnings with net income of $4.0M ($0.05 diluted EPS) vs a loss of $12.0M (-$0.16) a y | May 6, 2026 |
| CNTX | PRESS-RELEASE | mixed | 5/10 | Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-revenue biotech highlig | May 6, 2026 |
| INVA | 8-K | mixed | 5/10 | Innoviva reported Q1 2026 total revenue of $98.0M (+11% YoY, slightly below $101.6M consensus) and diluted EPS of $2.22, | May 6, 2026 |
| SRZNW | 8-K | neutral | 4/10 | Surrozen reported Q1 2026 revenue of $5.0M, beating consensus estimate of $4.0M, driven by a $5M milestone payment from | May 6, 2026 |
| APVO | 8-K | bullish | 6/10 | Aptevo announced positive clinical data from its RAINIER frontline AML trial, showing an 81% remission rate (CR/CRi) and | May 6, 2026 |
| NCNA | 6-K | bearish | 5/10 | NuCana published its 2025 UK Annual Report, reporting a net loss of £29.4M vs £19.0M in 2024, driven by a £12.6M non-cas | May 6, 2026 |
| PCVX | 8-K | bearish | 7/10 | Vaxcyte reported Q1 2026 net loss of $320.6M (-$2.30 per share), significantly worse than the consensus estimate of -$1. | May 6, 2026 |
| VNDA | 8-K | mixed | 6/10 | Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed | May 6, 2026 |
| ZVRA | 8-K | bullish | 6/10 | Zevra Therapeutics reported Q1 2026 net revenue of $36.2M (up 78% YoY) and GAAP diluted EPS of $0.60, massively beating | May 6, 2026 |
| TKNO | PRESS-RELEASE | bullish | 7/10 | Alpha Teknova reported Q1 2026 revenue of $11.1M (beat consensus of $10.2M by 8.6%) and EPS of -$0.08 (beat consensus -$ | May 6, 2026 |
| MNKD | PRESS-RELEASE | bearish | 8/10 | MannKind reported Q1 2026 GAAP EPS of -$0.05, a 600% miss vs. consensus of $0.01, and revenue of $90.2M, 14.4% below the | May 6, 2026 |
| DERM | PRESS-RELEASE | neutral | 1/10 | Journey Medical Corporation announced it will report its Q1 2026 results on May 13, 2026. | May 6, 2026 |
| ARGX | PRESS-RELEASE | neutral | 2/10 | argenx announced leadership transition at its AGM: Karen Massey appointed CEO, Tim Van Hauwermeiren becomes Chair. Share | May 6, 2026 |
| IFRX | 424B5 | bearish | 5/10 | InflaRx filed a preliminary prospectus supplement for an underwritten offering of ordinary shares. The size and pricing | May 6, 2026 |
| NAGE | 8-K | mixed | 5/10 | Niagen Bioscience reported Q1 2026 net sales of $31.5M (+3% YoY, +5% excluding divested segment) and GAAP net income of | May 6, 2026 |
| XNCR | 8-K | bearish | 7/10 | Xencor reported Q1 2026 revenue of $4.5M (down 86% YoY) and a net loss of $128.9M ($1.71 per share), massively missing c | May 6, 2026 |
| ASND | PRESS-RELEASE | neutral | 5/10 | Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegritide) in achondroplasi | May 6, 2026 |
| LXRX | 8-K | neutral | 4/10 | Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 million funded at clos | May 6, 2026 |
| ARQT | PRESS-RELEASE | mixed | 5/10 | Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M (+65% YoY), beating consensus of $103.7M, but EP | May 6, 2026 |
| MBX | 144 | neutral | 1/10 | Director/officer P. Kent Hawryluk filed Form 144 to sell 607 shares of MBX Biosciences, valued at approximately $17,934, | May 6, 2026 |
| RARE | CLUSTER | neutral | 2/10 | Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past | May 6, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK held its 26th Annual General Meeting on May 6, 2026, with all 25 resolutions passed by a majority. The filing is a r | May 6, 2026 |
| RGPX | 8-K | bearish | 6/10 | Regenerex Pharma terminated its CFO Kenneth Perry for cause following a committee review of audit-related findings. An i | May 6, 2026 |
| CLRB | 424B5 | bearish | 7/10 | Cellectar Biosciences is conducting a dilutive public offering of 1.6M shares at $2.65 (6.4% discount to last close) alo | May 6, 2026 |